Product Information
BREO ELLIPTA 200-25 MCG INHALR is a brand product labeled by GlaxoSmithKline LLC, priced at $5.3639 per EA under NDC 00173088214. Its NADAC has been published 547 times since Dec 23, 2015.
Strength
200; 25 ug/1; ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173088214
Classification
Brand
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Last Updated
6/17/2026
Active Ingredients
FLUTICASONE FUROATE; VILANTEROL TRIFENATATEApproval Type
New Drug (NDA)
FDA Application
NDA204275On Market Since
4/30/2015
Pharmacological Classes
Price Statistics
The NADAC for BREO ELLIPTA 200-25 MCG INHALR has been published 547 times since Dec 23, 2015, and over the history we have for it it has risen 43.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.3639 per EA |
|---|---|
| All-time high | $5.3913 (Oct 15, 2025) |
| All-time low | $3.6186 (Apr 20, 2016) |
| 52-week high | $5.3913 |
| 52-week low | $5.3586 |
| Median price | $4.8910 |
| Average price | $4.8127 |
| Largest weekly change | -8.5% (Apr 20, 2016) |
| Weeks tracked | 547 |
| Tracking since | Dec 23, 2015 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of BREO ELLIPTA 200-25 MCG INHALR?
The current National Average Drug Acquisition Cost (NADAC) for BREO ELLIPTA 200-25 MCG INHALR, manufactured by GlaxoSmithKline LLC, is $5.3639 per EA (NDC 00173088214), effective Jun 24, 2026.
How has the price of BREO ELLIPTA 200-25 MCG INHALR changed over time?
Over the history we have for it, the NADAC for BREO ELLIPTA 200-25 MCG INHALR has risen 43.8%. It has been tracked across 547 weekly CMS publications since Dec 23, 2015.
What are the highest and lowest recorded NADAC prices for BREO ELLIPTA 200-25 MCG INHALR?
Since Dec 23, 2015, the NADAC for BREO ELLIPTA 200-25 MCG INHALR has ranged from a low of $3.6186 (Apr 20, 2016) to a high of $5.3913 (Oct 15, 2025), with a median of $4.8910 per EA.
Are there cheaper alternatives to BREO ELLIPTA 200-25 MCG INHALR?
1 NADAC-published product shares the same active ingredient, strength, and dosage form as BREO ELLIPTA 200-25 MCG INHALR, but none are currently priced below it.
Who manufactures BREO ELLIPTA 200-25 MCG INHALR?
BREO ELLIPTA 200-25 MCG INHALR (NDC 00173088214) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.
Related Drugs
Same classification